This may explain why the inhibition of RANKL in transgenic FD mice rapidly converts the osteogenic fibrous-like tissue into hyper-mineralized bone [180], while bisphosphonates, which inhibit bone resorption but not osteoclast formation, do not modify the histopathology of the disease in both transgenic mice [181] and FD patients [141,182]. The gene discussed is TNFSF11; the disease is Fabry disease.